Cargando…
Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine
An Ad26.RSV.preF/RSV preF protein combination vaccine demonstrated 80.0% vaccine efficacy for the prevention of respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in a phase 2b study. In addition to neutralizing antibodies, Fc-effector functions are associated with protective...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688327/ https://www.ncbi.nlm.nih.gov/pubmed/37902399 http://dx.doi.org/10.1128/jvi.00771-23 |
_version_ | 1785152159542673408 |
---|---|
author | Bartsch, Yannic C. Cizmeci, Deniz Yuan, Dansu Mehta, Nickita Tolboom, Jeroen De Paepe, Els van Heesbeen, Roy Sadoff, Jerald Comeaux, Christy A. Heijnen, Esther Callendret, Benoit Alter, Galit Bastian, Arangassery Rosemary |
author_facet | Bartsch, Yannic C. Cizmeci, Deniz Yuan, Dansu Mehta, Nickita Tolboom, Jeroen De Paepe, Els van Heesbeen, Roy Sadoff, Jerald Comeaux, Christy A. Heijnen, Esther Callendret, Benoit Alter, Galit Bastian, Arangassery Rosemary |
author_sort | Bartsch, Yannic C. |
collection | PubMed |
description | An Ad26.RSV.preF/RSV preF protein combination vaccine demonstrated 80.0% vaccine efficacy for the prevention of respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in a phase 2b study. In addition to neutralizing antibodies, Fc-effector functions are associated with protective immunity against RSV. Here, vaccine-induced Fc-effector functions were evaluated for the Ad26.RSV.preF/RSV preF protein vaccine in a subset of participants enrolled in a phase 1/2a study. RSV preF-specific antibody subclasses, isotypes, Fcγ receptor binding, and Fc-effector functions were evaluated on days 1 (pre-vaccination), 15, 29, and 183. Compared with Ad26.RSV.preF or RSV preF protein alone, the combination vaccine induced greater Fc-effector functions, including antibody-dependent neutrophil phagocytosis and antibody-dependent natural killer cell activation. Despite RSV pre-exposure, antibody-dependent neutrophil phagocytosis and antibody-dependent natural killer cell activation were not observed at baseline but were induced de novo following vaccination. Compared with the individual vaccine components, the combination vaccine induced a more polyfunctional antibody response. IMPORTANCE: Respiratory syncytial virus (RSV) can cause serious illness in older adults (i.e., those aged ≥60 years). Because options for RSV prophylaxis and treatment are limited, the prevention of RSV-mediated illness in older adults remains an important unmet medical need. Data from prior studies suggest that Fc-effector functions are important for protection against RSV infection. In this work, we show that the investigational Ad26.RSV.preF/RSV preF protein vaccine induced Fc-effector functional immune responses in adults aged ≥60 years who were enrolled in a phase 1/2a regimen selection study of Ad26.RSV.preF/RSV preF protein. These results demonstrate the breadth of the immune responses induced by the Ad26.RSV.preF/RSV preF protein vaccine. |
format | Online Article Text |
id | pubmed-10688327 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-106883272023-12-01 Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine Bartsch, Yannic C. Cizmeci, Deniz Yuan, Dansu Mehta, Nickita Tolboom, Jeroen De Paepe, Els van Heesbeen, Roy Sadoff, Jerald Comeaux, Christy A. Heijnen, Esther Callendret, Benoit Alter, Galit Bastian, Arangassery Rosemary J Virol Vaccines and Antiviral Agents An Ad26.RSV.preF/RSV preF protein combination vaccine demonstrated 80.0% vaccine efficacy for the prevention of respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in a phase 2b study. In addition to neutralizing antibodies, Fc-effector functions are associated with protective immunity against RSV. Here, vaccine-induced Fc-effector functions were evaluated for the Ad26.RSV.preF/RSV preF protein vaccine in a subset of participants enrolled in a phase 1/2a study. RSV preF-specific antibody subclasses, isotypes, Fcγ receptor binding, and Fc-effector functions were evaluated on days 1 (pre-vaccination), 15, 29, and 183. Compared with Ad26.RSV.preF or RSV preF protein alone, the combination vaccine induced greater Fc-effector functions, including antibody-dependent neutrophil phagocytosis and antibody-dependent natural killer cell activation. Despite RSV pre-exposure, antibody-dependent neutrophil phagocytosis and antibody-dependent natural killer cell activation were not observed at baseline but were induced de novo following vaccination. Compared with the individual vaccine components, the combination vaccine induced a more polyfunctional antibody response. IMPORTANCE: Respiratory syncytial virus (RSV) can cause serious illness in older adults (i.e., those aged ≥60 years). Because options for RSV prophylaxis and treatment are limited, the prevention of RSV-mediated illness in older adults remains an important unmet medical need. Data from prior studies suggest that Fc-effector functions are important for protection against RSV infection. In this work, we show that the investigational Ad26.RSV.preF/RSV preF protein vaccine induced Fc-effector functional immune responses in adults aged ≥60 years who were enrolled in a phase 1/2a regimen selection study of Ad26.RSV.preF/RSV preF protein. These results demonstrate the breadth of the immune responses induced by the Ad26.RSV.preF/RSV preF protein vaccine. American Society for Microbiology 2023-10-30 /pmc/articles/PMC10688327/ /pubmed/37902399 http://dx.doi.org/10.1128/jvi.00771-23 Text en Copyright © 2023 Bartsch et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Vaccines and Antiviral Agents Bartsch, Yannic C. Cizmeci, Deniz Yuan, Dansu Mehta, Nickita Tolboom, Jeroen De Paepe, Els van Heesbeen, Roy Sadoff, Jerald Comeaux, Christy A. Heijnen, Esther Callendret, Benoit Alter, Galit Bastian, Arangassery Rosemary Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine |
title | Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine |
title_full | Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine |
title_fullStr | Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine |
title_full_unstemmed | Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine |
title_short | Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine |
title_sort | vaccine-induced antibody fc-effector functions in humans immunized with a combination ad26.rsv.pref/rsv pref protein vaccine |
topic | Vaccines and Antiviral Agents |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688327/ https://www.ncbi.nlm.nih.gov/pubmed/37902399 http://dx.doi.org/10.1128/jvi.00771-23 |
work_keys_str_mv | AT bartschyannicc vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine AT cizmecideniz vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine AT yuandansu vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine AT mehtanickita vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine AT tolboomjeroen vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine AT depaepeels vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine AT vanheesbeenroy vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine AT sadoffjerald vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine AT comeauxchristya vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine AT heijnenesther vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine AT callendretbenoit vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine AT altergalit vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine AT bastianarangasseryrosemary vaccineinducedantibodyfceffectorfunctionsinhumansimmunizedwithacombinationad26rsvprefrsvprefproteinvaccine |